Study S002338

Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02860923
Acronym: CRANIOEXE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 42
Start: 2017-01-11
Primary completion: 2018-06-30
Lead sponsor: University Hospital, Bordeaux
Conditions: Craniopharyngiomas; Hypothalamic Obesity
Interventions: DRUG:Exenatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: EUDRACT_NUMBER:2013-004755-21

Registered primary outcomes

Compare body weight change thanks to weighing machine [baseline and 6 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013451	Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial. Gatta-Cherifi B, European journal of endocrinology	2024	Randomized trial	PMID 38450721 DOI	registry reference RESULT:38450721